A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Rasha Kaddoura; Wafer A Dabdoob; Khalid Ahmed; Mohamed A Yassin

doi:10.3389/fmed.2023.1163137

A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Front Med (Lausanne). 2023 May 5:10:1163137. doi: 10.3389/fmed.2023.1163137. eCollection 2023.

Authors

Rasha Kaddoura¹, Wafer A Dabdoob¹, Khalid Ahmed¹, Mohamed A Yassin¹

Affiliation

¹ Hamad Medical Corporation, Doha, Qatar.

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.

Keywords: QT prolongation; chronic myeloid leukemia; dasatinib; heart failure; pleural effusion; ponatinib; pulmonary arterial hypertension; tyrosine kinase.

Publication types

Review